Big data in IBD: big progress for clinical practice.

Journal: Gut
Published Date:

Abstract

IBD is a complex multifactorial inflammatory disease of the gut driven by extrinsic and intrinsic factors, including host genetics, the immune system, environmental factors and the gut microbiome. Technological advancements such as next-generation sequencing, high-throughput omics data generation and molecular networks have catalysed IBD research. The advent of artificial intelligence, in particular, machine learning, and systems biology has opened the avenue for the efficient integration and interpretation of big datasets for discovering clinically translatable knowledge. In this narrative review, we discuss how big data integration and machine learning have been applied to translational IBD research. Approaches such as machine learning may enable patient stratification, prediction of disease progression and therapy responses for fine-tuning treatment options with positive impacts on cost, health and safety. We also outline the challenges and opportunities presented by machine learning and big data in clinical IBD research.

Authors

  • Nasim Sadat Seyed Tabib
    Department of Chronic Diseases, Metabolism and Ageing, TARGID, KU Leuven, Leuven, Belgium.
  • Matthew Madgwick
    Organisms and Ecosystems, Earlham Institute, Norwich, UK.
  • Padhmanand Sudhakar
    Department of Chronic Diseases, Metabolism and Ageing, TARGID, KU Leuven, Leuven, Belgium.
  • Bram Verstockt
    Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Tamas Korcsmaros
    Organisms and Ecosystems, Earlham Institute, Norwich, UK.
  • Séverine Vermeire
    Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Herestraat 49, 3000 Leuven, Belgium.